Phaseline

Companies › Theradex

Theradex: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Jul 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Pacritinib
Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Activin receptor type-1 inhibitor
JAK2, FLT3, ACVR1, IRAK1Phase 2Leukemia, Myelomonocytic, ChronicJul 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07033598PacritinibPhase 2Leukemia, Myelomonocytic, ChronicOncologyJul 2028

Targets

JAK2 (1) FLT3 (1) ACVR1 (1) IRAK1 (1)

Companies with the same targets

Swedish Orphan Biovitrum Bristol-Myers Squibb AbbVie GSK Daiichi Sankyo Chia Tai Tianqing Pharmaceutical Group Sun Pharmaceutical Industries Alfasigma Takeda Incyte

Companies built like this

NanoEcho Syncromune Galecto Biotech VSPharmTech BPGbio

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.